Day: May 2, 2025

Co-promotion with ARS Pharma based on cost sharing and performance-based revenue sharing. ALK to accelerate build-up of its US paediatric sales channel in a balanced way. Agreement does not change ALK’s revenue and earnings outlook for 2025.ALK (ALKB.DC / OMX: ALK B) today announced a 4-year agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY) to co-promote the neffy® adrenaline (epinephrine) nasal spray to up to 9,000 named paediatricians in the USA. These paediatricians currently account for close to 10% of all adrenaline auto-injector prescriptions in the USA.  The agreement is expected to give ALK improved access to US paediatricians, providing also attractive synergies to ALK’s existing product portfolio. neffy® is the only approved needle-free treatment for life-threatening type I allergic reactions,...

SYDNEY, May 02, 2025 (GLOBE NEWSWIRE) — IREN Limited (NASDAQ: IREN) (together with its subsidiaries, “IREN”) today announced that it will release its financial results for the three and nine-months ended March 31, 2025, on Wednesday, May 14, 2025 and host a conference call beginning at 5:00 p.m. Eastern Time. The webcast will be recorded, and the replay will be accessible shortly after the event at https://iren.com/investor/events-and-presentationsWebcast and Conference Call DetailsTime & Date: 5:00 p.m. Eastern Time, Wednesday, May 14, 2025    Participant Registration Link    Live Webcast Use this link    Phone Dial-In with Live Q&A Use this link  Participants joining the conference call via the phone dial-in option will receive their dial-in number, passcode and PIN following registration...

Vilnius, Lithuania, May 02, 2025 (GLOBE NEWSWIRE) — As at the end of April 2025, the net asset value (NAV) of SUTNTIB AB Tewox decreased to EUR 42,086,793, compared to previously determined NAV at the end of March 2025, which was EUR 42,415,003. The share price decreased to EUR 1.0053, from EUR 1.0132 at the end of March 2025. The pro-forma internal rate of return (IRR) decreased to 0.18%, compared to previously announced IRR of 0.45% at the end of March 2025. Contact person for further information: Paulius Nevinskas Manager of the Investment Company paulius.nevinskas@lordslb.lt https://lordslb.lt/tewox_bonds/

CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 8:00 am PT/11:00 am ET. The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class...

MONTREAL, May 02, 2025 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) plans to release its first quarter 2025 results on Tuesday, May 13, 2025 before market opens. Senior management will host a conference call on the same day at 10 a.m. Eastern Time to discuss the Corporation’s financial and operational results. Participants may join the conference call via webcast or by dialing-in as follows: Webcast link: https://edge.media-server.com/mmc/p/48g2kxgq Instructions for obtaining conference call dial-in numbers:Click on the following call link and complete the online registration form.https://register-conf.media-server.com/register/BI84408f0b334445fd8c5977ae41b1dd02Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation...